beyond|AESTHETICS Owner Leslie Petersen, NP, Accepted into Elite Dr. Mauricio de Maio MD Codes™ Fellowship Program




beyond|AESTHETICS Owner Leslie Petersen, NP, Accepted into Elite Dr. Mauricio de Maio MD Codes™ Fellowship Program

Camarillo, CA, Oct. 21, 2025 (GLOBE NEWSWIRE) — beyond|AESTHETICS is proud to announce that its owner, Leslie Petersen, NP, has been selected as one of only 15 individuals nationally for the highly coveted Dr. Mauricio de Maio MD Codes™ fellowship program for the 2025-2026 term. This prestigious acceptance underscores Mrs. Petersen’s commitment to excellence in the field of aesthetic medicine.

Dr. Mauricio de Maio is an internationally recognized innovator and thought leader in aesthetic medicine, whose revolutionary MD Codes system has been widely adopted as the global gold standard for facial rejuvenation using hyaluronic acid dermal fillers. The MD Codes platform, promoted by the Allergan Medical Institute™ (AMI), is renowned for its utilization of the JUVÉDERM® collection of fillers to achieve precise, natural-looking, and harmonious results.

“I am incredibly honored and excited to be accepted into Dr. de Maio’s MD Codes fellowship program,” said Leslie Petersen, NP. “This is a tremendous opportunity to learn directly from the master himself and to bring the most advanced and effective aesthetic techniques to more providers in the country and to our patients at beyond|AESTHETICS.”

Benefits for beyond|AESTHETICS and Patients

This unparalleled fellowship will significantly enhance the offerings at beyond|AESTHETICS and provide substantial benefits for its patients:

• Access to Cutting-Edge Techniques: Mrs. Petersen will gain in-depth knowledge and hands-on training in the most advanced MD Codes protocols directly from Dr. de Maio. This will translate into even more precise, effective, and natural-looking results for patients.
• Gold Standard Treatment: Patients at beyond|AESTHETICS will receive treatments based on the globally recognized gold standard for facial rejuvenation with dermal fillers, ensuring the highest level of care and optimal outcomes.
• Enhanced Expertise: The intensive training will further elevate Mrs. Petersen’s already extensive expertise, solidifying beyond|AESTHETICS’s position as a leader in aesthetic medicine in the region.
• Certified Trainer Status: Upon completion of the program, Leslie Petersen, NP, will become a certified trainer for MD Codes. This not only signifies her mastery of the system but also opens avenues for beyond|AESTHETICS to host training sessions and contribute to the education of other aesthetic professionals.
• Personalized and Harmonious Results: The MD Codes system focuses on individualized treatment plans that respect natural facial anatomy, ensuring that each patient receives a tailored approach for harmonious and aesthetically pleasing results.

beyond|AESTHETICS is dedicated to providing its patients with the safest and most effective aesthetic treatments. Leslie Petersen’s participation in the Dr. Mauricio de Maio MD Codes fellowship program reinforces this commitment and will enable the practice to deliver even higher standards of care and innovation.

About beyond|AESTHETICS

beyond|AESTHETICS is a premier aesthetic practice dedicated to providing advanced and personalized cosmetic treatments. Led by Leslie Petersen, NP, the practice focuses on natural-looking results and patient satisfaction through a comprehensive range of services.

CONTACT: Leslie Petersen, NP
Owner, beyond|AESTHETICS
Phone: 805-312-7070
Email: info@seewhatsbeyond.com
Website: www.seewhatsbeyond.com

Glo & Spa-rkle Aesthetics and Medspa Celebrates 700-Plus 5-Star Google Reviews, Cementing Rank as Best Laser Tattoo Removal Medspa in Lubbock, Texas.




Glo & Spa-rkle Aesthetics and Medspa Celebrates 700-Plus 5-Star Google Reviews, Cementing Rank as Best Laser Tattoo Removal Medspa in Lubbock, Texas.

Glo & Spa-rkle Aesthetics and Medical Spa achieves a significant milestone, reinforcing its commitment to excellence in aesthetic and wellness services.

Lubbock, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) — Glo & Spa-rkle Aesthetics and Medical Spa, a leading name in the aesthetic and wellness industry, proudly announces the achievement of its 700-plus 5-star Google reviews. This milestone underscores the medspa’s dedication to providing exceptional service and results, particularly in the realm of laser tattoo removal, where it has been recognized as the best laser tattoo removal service in Lubbock, Texas.

Located in the heart of Lubbock, Glo & Spa-rkle has built a reputation for excellence by offering a wide range of innovative treatments designed to enhance beauty, health, and confidence. The medspa’s comprehensive offerings include neuromodulators, laser treatments, non-surgical face and neck lifts, body contouring, advanced RF microneedling, medical weight loss programs, PDO thread lifts and dermal fillers. Additionally, the medspa specializes in regenerative therapies, such as biostimulators, exosomes, and polydeoxyribonucleotide (PDRN), to support natural healing and rejuvenation.

Glo & Spa-rkle’s commitment to personalized care and cutting-edge technology has been a cornerstone of its success. The medspa’s use of ultrasound-guided aesthetic injections of dermal fillers ensures optimal results with minimal risk, further enhancing its reputation for safety and precision.

“Achieving our 700-plus 5-star Google reviews is a testament to the hard work, exceptional customer service  and dedication of our entire team,” Fa-tia Johnson, the lead Nurse Practitioner and owner of Glo & Spa-rkle Aesthetics and Medical Spa. “We are deeply grateful to our clients for their trust and support, and we remain committed to delivering the highest quality aesthetic and wellness services.”

The recognition as the best laser tattoo removal provider in Lubbock is a reflection of Glo & Spa-rkle’s unwavering focus on client satisfaction and exceptional outcomes. The medspa’s state-of-the-art Picoway laser tattoo removal services are renowned for their effectiveness and safety, helping clients achieve clear, tattoo-free skin with confidence.

As Glo & Spa-rkle continues to grow and evolve, it remains dedicated to empowering clients to embrace their unique beauty and thrive on their wellness journey. The medspa’s mission to deliver tailored treatments in a welcoming, judgment-free environment has resonated with clients, as evidenced by the overwhelming positive feedback and reviews.

Glo & Spa-rkle Aesthetics and Medical Spa looks forward to continuing its tradition of excellence, setting new standards in the aesthetic and wellness industry, and celebrating many more milestones in the future.

About Glo & Spa-rkle Aesthetics and Medical Spa

Glo & Spa-rkle is a premier aesthetic and wellness med spa located in Lubbock, Texas, dedicated to enhancing beauty, health, and confidence through innovative, high-quality treatments. Catering directly to clients, we offer a curated selection of services designed to promote skin and body rejuvenation, fostering a renewed sense of self-assurance. Our comprehensive offerings include neuromodulators, laser treatments, non-surgical face and neck lifts with PDO threads and EMFACE, body contouring, advanced RF microneedling, medical weight loss programs, and dermal fillers. Additionally, we specialize in regenerative therapies, such as biostimulators, exosomes, and polydeoxyribonucleotide (PDRN), to support natural healing and rejuvenation. For enhanced safety and precision, we utilize ultrasound-guided aesthetic injections of dermal fillers, ensuring optimal results with minimal risk. At Glo & Spa-rkle, we prioritize personalized care, leveraging cutting-edge technology to deliver tailored treatments in a welcoming, judgment-free environment. Our mission is to empower every client to embrace their unique beauty and thrive on their wellness journey. As a client-focused small to medium-sized enterprise, Glo & Spa-rkle generates revenue through direct-to-consumer aesthetic and wellness services, delivering exceptional outcomes with every visit. 

Press inquiries

Glo & Spa-rkle Aesthetics and Medical Spa
https://gloandsparkle.com
Lauren Boutwell
lauren.boutwell@gloandsparkle.com
8066423992
10607 Quaker Ave Suite 103, Lubbock Texas 79424.

The address changing in December 2025 to 4513 114th Street Lubbock, Texas 79424.

A video accompanying this announcement is available at https://www.youtube.com/embed/1DEW5zCZurQ

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million




Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

CHICAGO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has acquired an additional $200,000 worth of Ethereum (ETH), bringing the Company’s total investment in ETH to $2 million.

This purchase was executed under Cosmos Health’s previously announced $300 million digital assets facility, which underpins the Company’s strategy to broaden and strengthen its portfolio through targeted digital asset investments.

Greg Siokas, CEO of Cosmos Health, stated: “Reaching the $2 million milestone in our Ethereum investment marks another important step in our digital asset expansion strategy. We remain steadfast in our commitment to leveraging our $300 million financing facility to further diversify and enhance our long-term asset base.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

IPSEN – Buy-back programme – Art 5 of MAR – Week 42 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 42 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 42_2025

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year




Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

ALBANY, N.Y., Oct. 21, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced its Burlington, MA sterile drug product facility has been named “Manufacturer of the Year” by the Massachusetts Legislative Manufacturing Caucus. The award was presented at the 10th Annual Manufacturing Awards Ceremony, held on Oct. 21 at Gillette Stadium.

Curia’s Burlington site has been part of the company’s network since 2010. The facility specializes in drug product manufacturing of vials and prefilled syringes for late-stage clinical trials and commercial products. The site is known for its capabilities to handle solvent-based processes, highly viscous products and controlled substances. It also houses an on-site process development lab supporting mixing studies, scale-up and formulation development.

“Curia employees play a crucial role in producing medicines patients can trust, guided by the most stringent quality standards,” said Mari-Kate Alter, General Manager and Site Head, Curia Burlington. “While our direct clients are pharmaceutical companies, we come to work each day with patients in mind. We are honored to contribute to improving patient lives and are proud to be recognized for our role in Massachusetts’ manufacturing ecosystem.”

Curia’s sterile drug product capabilities include working with complex APIs, potent and cytotoxic compounds, highly viscous formulations and controlled substances, from clinical to commercial scale, at four advanced facilities around the world. The Burlington site is part of Curia’s global network of sterile fill-finish facilities, which includes clinical manufacturing in Camarillo, CA and Glasgow, UK, as well as commercial and clinical capabilities in Albuquerque, NM.

The Manufacturing Caucus, formed in 2014, includes more than 70 Massachusetts legislators focused on strengthening the state’s manufacturing sector through workforce training, innovation support and apprenticeship programs.

“This is an exciting time for committed manufacturers like Curia who embody ‘Making It in Massachusetts,’” said State Representative Jeffrey Roy, House Chair of the Manufacturing Caucus. “Manufacturing remains vital to our economy and future, providing innovation and high-paying jobs for residents across the Commonwealth. We look forward to celebrating Curia at the 10th Annual Manufacturing Awards Ceremony at Gillette Stadium on Tuesday, Oct. 21, 2025.”

About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20 global sites and 3,200 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs, sterile drug product and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory-compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025




Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:                                        
David L. Fischel                                        
Chairman and Chief Executive Officer                        
                                                        
Kimberly Peery                                                
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers




Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers

• IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studies
• First patient dosing planned before year-end 2025 at leading cancer centers in collaboration with top key opinion leaders
• Program validates Dewpoint’s condensate-modulator discovery platform and the value of agile, integrated partnerships in accelerating novel drug development.

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) — Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for DPTX3186, a first-in-class, only-in-class oral condensate modulator (c-mod) designed to selectively disrupt oncogenic Wnt/β-catenin signaling in tumors. Dewpoint plans to begin dosing its first patient before the end of 2025 in a combined Phase 1/2 trial conducted in partnership with leading cancer centers and key opinion leaders in gastric and other Wnt-driven cancers.

The IND opening marks a significant milestone in Dewpoint’s journey and underscores the strength of its partnership with Evotec, a global drug discovery and development company. Evotec leveraged its deep expertise in drug development to provide integrated support across preclinical, regulatory, and CMC, helping to translate a de novo candidate emerging from Dewpoint’s proprietary c-mod platform into a robust and clinically ready investigational therapy.

“Evotec’s depth of experience and proven track record in advancing first-in-class small molecules through their Evotec INDiGO^® platform made them an ideal partner for this effort,” said Ameet Nathwani, Chief Executive Officer of Dewpoint Therapeutics. “Their scientific rigor and development agility were instrumental in helping us take a novel condensate-derived mechanism from concept to IND. For a young biotech company like Dewpoint moving into the clinic for the first time, working alongside a partner of Evotec’s caliber significantly de-risked and accelerated our path to the clinic.”

Discovered and optimized using Dewpoint’s proprietary condensate-modulating drug discovery platform, DPTX3186 uniquely forces β-catenin to concentrate within an inactive condensate inside tumor cells. This novel spatial sequestration mechanism overcomes historic toxicity hurdles that have plagued previous Wnt-targeting approaches. The program is paired with an innovative biomarker strategy tailored to the drug’s condensate-specific mechanism, designed to provide early, precise readouts of pharmacodynamic effect.

“Dosing our first patient this year will be a defining moment for condensate biology and Dewpoint,” said Isaac Klein, MD, PhD, Chief Scientific Officer of Dewpoint Therapeutics. “DPTX3186 is the only molecule of its kind: an oral small-molecule c-mod tackling a historically undruggable pathway with a differentiated safety profile. Its discovery on our platform, the bespoke biomarker strategy, and the caliber of partners supporting this trial reflect the transformative potential of condensate science to rewrite what is possible in drug discovery and development.”

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Evotec is proud to support Dewpoint in translating an entirely new modality from biology to clinic. The DPTX3186 program exemplifies how next-generation science and disciplined execution must go hand in hand. Dewpoint’s advanced expertise in condensate biology and Evotec’s integrated development platform capabilities have together enabled a smoother, more de-risked path to IND. This project reflects the kind of collaborative, high-science partnerships that will define the future of innovative drug development.”

The initial study will evaluate the safety, pharmacokinetics, and preliminary efficacy of DPTX3186 as a single agent, with a focus on metastatic gastric cancer. Planned expansion cohorts will include combination regimens and additional tumor types. Dewpoint’s strategic collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma, alongside its AI/ML-enabled discovery platform, continue to fuel a pipeline spanning oncology, neurodegenerative, cardiopulmonary, and metabolic diseases.

About Dewpoint
Dewpoint is a clinical-stage biotech company, leading the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. The realization that a vast range of conditions are regulated by or arise from the dysfunction of condensates has provided new possibilities for modulating the function of high-value targets previously deemed ‘undruggable’, opening unexplored avenues to identify hundreds of novel therapeutic targets. Dewpoint’s proprietary AI/ML-powered state-of-the-art integrated technology underlies a drug discovery pipeline that spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Through collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma Corporation, Dewpoint pushes the boundaries to accelerate the translation of condensate biology into medicine for patients suffering from difficult-to-treat diseases. Learn more at Dewpointx.com and follow us on  LinkedIn. 

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.
Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

About Condensates   
Condensates are membraneless organelles that form dynamically throughout the cell via a process called phase separation. These subcellular compartments organize and concentrate molecules within cells to enable a diversity of key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases, including cancer, diabetes, cardiopulmonary and neurological disorders. Condensate-modulating drugs (c-mods) potentially provide novel therapeutic options for complex diseases and historically undruggable targets. Learn more about condensate science at Condensates.com.  

Dewpoint Therapeutics
Media Contact
media@dewpointx.com

Investor Contact
IR@dewpointx.com

Evotec SE
Media
Susanne Kreuter 
VP Head of Strategic Marketing 
Susanne.Kreuter@evotec.com  

Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

WORK Medical Technology Group LTD Announces US$1 Million Equity Investment in Neologics Bioscience




WORK Medical Technology Group LTD Announces US$1 Million Equity Investment in Neologics Bioscience

Hangzhou, China, Oct. 21, 2025 (GLOBE NEWSWIRE) — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has entered into an investment agreement (the “Investment Agreement”) with Neologics Bioscience Inc. (“Neologics”), a Delaware-based medical technology company specializing in research and development of medical technologies, with a focus on the integration of artificial intelligence and medicine (the “R&D”), to invest US$1 million in cash to acquire a 10% equity interest in Neologics. Pursuant to the Investment Agreement, WORK Medical has agreed to subscribe for newly issued shares of Neologics, representing a 10% ownership interest on a post-investment basis. Following the investment, Neologics’s total capital reserve will increase to US$10 million, with its existing shareholder retaining a 90% ownership interest. According to the Investment Agreement, WORK Medical has corporate governance rights commensurate with its 10% equity interest in Neologics, including, shareholder rights with respect to nominating board members. Additionally, WORK Medical has a right of first refusal to purchase any equity interests offered by Neologics, on terms no less favorable than those offered to third parties.

The investment proceeds are expected to be primarily used to support Neologics’s operations, R&D, market expansion, talent acquisition, and other legitimate business purposes. Neologics has agreed to complete all necessary corporate registration, shareholder filings, and the issuance of an equity certificate within 20 working days following the execution of the Investment Agreement.

Mr. Shuang Wu, chief executive officer and chairman of the board of directors of WORK Medical, commented: “We are excited to partner with Neologics, which marks a key step in advancing our strategic focus on innovation and global collaboration in the medical technology field. By combining Neologics’s R&D capabilities with WORK Medical’s industry experience and operational strengths, we expect this partnership to unlock synergies and growth potential. Together, we aim to foster technological innovation, drive mutual advancement, and deliver sustainable value to both companies and our stakeholders.”

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

For more information, please contact:

WORK Medical Technology Group LTD
Investor Relations Department
Email: ir@workmedtech.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Armada and Eclipse Energy Partner to Accelerate Commercialization of Critical Edge Technologies for Global Industrial Challenges




Armada and Eclipse Energy Partner to Accelerate Commercialization of Critical Edge Technologies for Global Industrial Challenges

SAN FRANCISCO and HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) — Armada and Eclipse Energy (formerly Gold H2) today announced a strategic partnership to accelerate the commercialization and reliability of critical edge technologies designed to meet industrial-scale challenges worldwide. Together, the companies are aligning their expertise to transform how clean energy and AI infrastructure are deployed at scale.

“The demand for power in the datacenter sector has never been greater,” said Prabhdeep Sekhon, CEO of Eclipse Energy. “By bringing our innovative subsurface solutions into partnership with Armada, we are addressing both the urgent need for clean, reliable power and the imperative to build with sustainability in mind.”

Armada has established itself as a disruptive force for edge computing, achieving rapid success in deploying next-generation, full-stack infrastructure to meet surging digital demand. The company is scaling quickly, with a trajectory to become the hyperscaler for the edge and redefine how these computing powerhouses are built, powered, and maintained across the globe.

“Eclipse Energy’s bioconversion of legacy oil fields into clean hydrogen is a natural complement to Armada’s Galleon Modular Data Centers,” said Dan Wright, CEO and Co-Founder of Armada. “By pairing their subsurface hydrogen production with our modular compute assets, we can deliver truly off-grid, carbon-aware data centers and prove that scalable performance and sustainable energy can go hand in hand.”

Eclipse Energy combines geoscience, engineering, and deep microbiology to redefine the subsurface as a clean energy asset. Recent accomplishments like the successful completion of the world’s first field trial demonstrating subsurface bio-stimulated hydrogen production established a roadmap to produce this low-cost, low-carbon energy using existing infrastructure. Without the need for new drilling, electrolysis, or energy-intensive surface facilities, this approach is primed to become a truly affordable and accessible source of energy.

About Armada
Armada is a full-stack edge infrastructure company delivering compute, storage, connectivity, and AI/ML capabilities to the most remote and rugged industrial environments on Earth. From energy to defense, Armada enables organizations to operate at the edge—without compromise.

About Eclipse Energy
Eclipse Energy is a climate technology and energy company revolutionizing energy through subsurface biotechnology. Using microbiology coupled with existing hydrocarbon infrastructure, Eclipse Energy’s proprietary biotechnology transforms depleted oil fields into cost-effective, sustainable hydrogen underground. Working with leading energy companies, clean energy investors, operators, off takers, and public institutions, Eclipse Energy delivers a scalable, sustainable alternative to conventional and emerging energy production and decarbonization methods.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/397a7d17-0e33-4d99-9938-d6ac2bbbe391

CONTACT: Media Contact
Libby Spicer
Libby@eclipseenergy.co

Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies




Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

Three Independent Studies Published in “Alzheimer’s Research & Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology” Validate Nexalin’s Non-Invasive Approach with Consistent Cognitive and Neuroimaging Benefits

HOUSTON, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that three independently published, peer-reviewed clinical studies, coupled with a growing body of internal data, collectively demonstrate the ability of its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS™ technology—to improve cognition, restore brain activity, and enhance neuron connectivity in patients with Alzheimer’s disease (AD).

Each study was announced separately upon publication. Taken together, the results provide a convergent body of evidence validating Nexalin’s differentiated, non-invasive approach to treating Alzheimer’s disease.

1. TRANSFORM-AD – Alzheimer’s Research & Therapy
This randomized, double-blind clinical trial (46 patients) evaluated 30 one-hour DIFS sessions over 15 days. Patients receiving active stimulation demonstrated immediate improvements in MMSE and MoCA scores, alongside enhanced hippocampal theta-gamma coupling and increased low-frequency fluctuations on fMRI. The study provided the first rigorous evidence of hippocampal activation and short-term cognitive benefit from DIFS in Alzheimer’s and Dementia.

2. Altered Neuronal Activity – Journal of Alzheimer’s Disease
A subsequent publication used resting-state fMRI to analyze brain network changes. Results demonstrated significant increases in fALFF and regional homogeneity (ReHo) in key prefrontal and memory-related regions, including the left middle frontal gyrus and right parahippocampal gyrus. These findings underscored DIFS’ ability to restore regional neuronal synchronization and blood flow in disrupted networks.

3. Modulation of Cortical and Hippocampal Connectivity – Radiology
The most recent publication, appearing in Radiology (June 2025), showed that DIFS significantly improved cognition while enhancing connectivity between the hippocampus and cortical regions, including the middle cingulate and middle frontal gyri. Network-level gains were also observed across the default mode and frontoparietal networks—systems critical to memory and executive function. Notably, cognitive improvements correlated with imaging findings, directly linking brain network modulation to functional outcomes.

With the global Alzheimer’s market projected to exceed $20 billion annually, current treatments remain dominated by pharmacologic therapies targeting amyloid or tau proteins. These drugs, while representing some progress, often deliver modest clinical benefits, and carry significant safety risks and high costs.

Nexalin’s DIFS technology is fundamentally different:

• Drug-free and non-invasive, with no reported serious side effects.
• Targeted to network dysfunction, addressing disrupted brain connectivity rather than protein accumulation.
• Safe and scalable, with demonstrated tolerability in elderly patients.

The Company believes this will position Nexalin as a potential paradigm-shifting solution for patients seeking accessible, safe, effective alternatives to drug regimens, at considerably less cost than pharmaceuticals.

“The strength of these three publications lies in their convergence,” said Mark White, CEO of Nexalin Technology. “Each study explores a different dimension of the disease—cognition, regional activity, and functional connectivity—and all point to the same conclusion: Nexalin’s DIFS technology has the potential to restore brain networks and improve cognitive function in Alzheimer’s disease. Collectively, they represent one of the most compelling non-invasive data sets to date in this field.”

Dr. David Owens, Chief Medical Officer of Nexalin, added, “These studies together validate the mechanism of action for DIFS. By showing consistent improvements across multiple imaging modalities and clinical outcomes, we now have a holistic picture of how DIFS may counteract the disruptions that drive cognitive decline in Alzheimer’s. This growing body of evidence strongly supports further development and regulatory advancement.”

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:

Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com